Cencora stock gains 1.07 percent as guidance rises

Published on 10/07/2026 at 15:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cencora stock was trading at USD 319.77 on October 7, 2026. Fiscal Q3 revenue reached USD 84.8 billion and adjusted EPS grew 12.0 percent after results.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Cencora Inc. (ISIN US03073E1055) stock was trading at USD 319.77 on the NYSE at 9:57 a.m. ET on October 7, 2026, up 1.07 percent from the prior close. The move comes as investors weigh a fiscal third-quarter report that lifted the company’s adjusted earnings outlook.

Guidance rises after strong quarter

According to Yahoo Finance on August 5, 2026, Cencora raised fiscal 2026 adjusted EPS guidance to USD 17.75-17.95 from USD 17.70-17.90. Adjusted EPS grew 12.0 percent in the fiscal third quarter, supported in part by USD 1.0 billion in share repurchases.

Business Wire reported that fiscal third-quarter revenue rose 5.1 percent year over year to USD 84.8 billion for the period ended June 30, 2026. GAAP diluted EPS was USD 3.94, compared with USD 3.52 in the prior-year quarter.

Profit growth outpaces revenue

The earnings mix is the important distinction for Cencora. The company’s adjusted operating income grew 17.0 percent while revenue increased 5.1 percent, showing that profit expansion exceeded top-line growth in fiscal Q3 2026.

The quarter also included a 61-basis-point expansion in adjusted gross margin to 4.16 percent, according to Yahoo Finance. OneOncology contributed to the margin improvement, but the acquisition also increased operating expenses, leaving investors to judge whether the benefit can persist.

Consensus target stays above price

According to MarketBeat on October 2, 2026, 16 analysts hold a Moderate Buy consensus, with 13 Buy ratings and three Holds. The average 12-month target is USD 370.85, with a high of USD 440.00 and a low of USD 285.00.

Using the October 7 price of USD 319.77, the average target lies 16.0 percent above the stock. That comparison gives the market move a clear valuation reference, while the 5.1 percent revenue growth shows why the outlook depends on continued margin execution rather than sales growth alone.

Cencora stock trades above USD 319

Cencora stock was last at USD 319.77 on the NYSE on October 7, 2026 at 9:57 a.m. ET. Its 52-week range was USD 244.82 to USD 377.54, placing the price 15.3 percent below the yearly high.